Clinical Trials · NCT05498610
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 24
- Start date
- Aug 2022
- Locations
- 1 site, China
- Primary endpoint
- AUC0-∞,NNC0480-0389,SD Area under the NNC0480-0389 plasma concentration-time curve from time 0 to infinity after a single dose (SD)